A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 346 participants.

Also called NCT04754334

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 346 participants (enrolled count) (from the registry)
Sponsor
  • Integrium Registry lists this organization as a collaborator
  • Oramed, Ltd. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04754334
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04754334. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-16 (actual); primary completion 2023-01-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
ORMD-0801
Intervention (Other)
Placebo
Lead sponsor
Oramed, Ltd. (class: industry)
Collaborator
Integrium (class: industry)

Record details

Record id
cardio:ct-nct04754334
Content hash
2ee882f9a9cacd16863bb33801ea2a493c1f377fb90eab237bbbeda3cbdac5ca